Nano-sized drug delivery systems to potentiate the immune checkpoint blockade therapy

References

• Weiner LM. Cancer immunotherapy — the endgame begins. N Engl J Med. 2008;358(25):2664–2665.
   PubMed Web of Science ®Google Scholar
• Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14(1):73.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Weiner GJ, Pardoll DM. Cancer Immunotherapy Comes of Age. J Clin Oncol. 2011;29(36):4828–4836.
   PubMed Web of Science ®Google Scholar
• Queirolo P, Boutros A, Tanda E, et al. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. Semin Cancer Biol. 2019;59:290–297.
   PubMed Web of Science ®Google Scholar
• Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. Jnci. 2013;105(4):256–265.
   PubMed Web of Science ®Google Scholar
• Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–1086.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974–1982.
   PubMed Web of Science ®Google Scholar
• Nishino M, Ramaiya NH, Hatabu H, et al. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017;14(11):655–668.
   PubMed Web of Science ®Google Scholar
• Chen Q, Sun T, Jiang C. Recent advancements in nanomedicine for ‘cold’ tumor immunotherapy. Nano-Micro Lett. 2021;13(1):92.
   PubMedGoogle Scholar
• Haanen JB. Converting cold into hot tumors by combining immunotherapies. Cell. 2017;170(6):1055–1056.
   PubMed Web of Science ®Google Scholar
• Yang L, Li A, Lei Q, et al. Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment. J Hematol Oncol. 2019;12(1):125.
   PubMedGoogle Scholar
• Kyu Shim M, Yang S, Sun I-C, et al. Tumor-activated carrier-free prodrug nanoparticles for targeted cancer immunotherapy: preclinical evidence for safe and effective drug delivery. Adv Drug Deliv Rev. 2022;183:114177.
   PubMedGoogle Scholar
• Li J, Stanger BZ. Cell cycle regulation meets tumor immunosuppression. Trends Immunol. 2020;41(10):859–863.
   PubMed Web of Science ®Google Scholar
• Choi J, Shim MK, Yang S, et al. Visible-light-triggered prodrug nanoparticles combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. ACS Nano. 2021;15(7):12086–12098.
   Google Scholar
• Yang S, Shim MK, Kim WJ, et al. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity. Biomaterials. 2021;272:120791.
   PubMed Web of Science ®Google Scholar
• Sweeney EE, Cano-Mejia J, Fernandes R. Photothermal therapy generates a thermal window of immunogenic cell death in neuroblastoma. Small. 2018;14(20):1800678.
   PubMed Web of Science ®Google Scholar
• Yang S, Sun I-C, Hwang HS, et al. Rediscovery of nanoparticle-based therapeutics: boosting immunogenic cell death for potential application in cancer immunotherapy. J Mater Chem B. 2021;9(19):3983–4001.
   PubMed Web of Science ®Google Scholar
• Li J, Wang S, Lin X, et al. Red blood cell-mimic nanocatalyst triggering radical storm to augment cancer immunotherapy. Nano-Micro Lett. 2022;14(1):57.
   PubMed Web of Science ®Google Scholar
• Wu M, Zheng D, Zhang D, et al. Converting immune cold into hot by biosynthetic functional vesicles to boost systematic antitumor immunity. iScience. 2020;23(7):101341.
   PubMedGoogle Scholar
• Hernandez C, Huebener P, Schwabe RF. Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene. 2016;35(46):5931–5941.
   PubMed Web of Science ®Google Scholar
• Park S-Y, Kim I-S. Engulfment signals and the phagocytic machinery for apoptotic cell clearance. Exp Mol Med. 2017;49(5):e331–e331.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31(1):51–72.
   PubMed Web of Science ®Google Scholar
• Ngwa W, Irabor OC, Schoenfeld JD, et al. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018;18(5):313–322.
   PubMed Web of Science ®Google Scholar
• Qi J, Jin F, Xu X, et al. Combination cancer immunotherapy of nanoparticle-based immunogenic cell death inducers and immune checkpoint inhibitors. Int J Nanomed. 2021;16:1435–1456.
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang G, Chen Y, et al. Immunogenic cell death in cancer therapy: present and emerging inducers. J Cell Mol Med. 2019;23(8):4854–4865.
   PubMed Web of Science ®Google Scholar
• Lim S, Park J, Shim MK, et al. Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy. Theranostics. 2019;9(25):7906–7923.
   PubMed Web of Science ®Google Scholar
• Jung B, Shim M-K, Park M-J, et al. Hydrophobically modified polysaccharide-based on polysialic acid nanoparticles as carriers for anticancer drugs. Int J Pharm. 2017;520(1):111–118.
   PubMedGoogle Scholar
• Jang EH, Shim MK, Kim GL, et al. Hypoxia-responsive folic acid conjugated glycol chitosan nanoparticle for enhanced tumor targeting treatment. Int J Pharm. 2020;580:119237.
   PubMedGoogle Scholar
• Shim MK, Na J, Cho IK, et al. Targeting of claudin-4 by Clostridium perfringens enterotoxin-conjugated polysialic acid nanoparticles for pancreatic cancer therapy. J Control Release. 2021;331:434–442.
   PubMedGoogle Scholar
• Ryu JH, Koo H, Sun I-C, et al. Tumor-targeting multi-functional nanoparticles for theragnosis: new paradigm for cancer therapy. Adv Drug Deliv Rev. 2012;64(13):1447–1458.
   PubMed Web of Science ®Google Scholar
• Maruyama K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev. 2011;63(3):161–169.
   PubMed Web of Science ®Google Scholar
• Song C, Ouyang Z, Guo H, et al. Core–shell tecto dendrimers enable enhanced tumor MR imaging through an amplified EPR effect. Biomacromolecules. 2021;22(5):2181–2188.
   PubMedGoogle Scholar
• Garrigue P, Tang J, Ding L, et al. Self-assembling supramolecular dendrimer nanosystem for PET imaging of tumors. Proc Natl Acad Sci. 2018;115(45):11454–11459.
   PubMed Web of Science ®Google Scholar
• Iyer AK, Greish K, Seki T, et al. Polymeric micelles of zinc protoporphyrin for tumor targeted delivery based on EPR effect and singlet oxygen generation. J Drug Target. 2007;15(7–8):496–506.
   PubMed Web of Science ®Google Scholar
• Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63(3):131–135.
   PubMed Web of Science ®Google Scholar
• Cho I-H, Shim MK, Jung B, et al. Heat shock responsive drug delivery system based on mesoporous silica nanoparticles coated with temperature sensitive gatekeeper. Microporous Mesoporous Mater. 2017;253:96–101.
   Web of Science ®Google Scholar
• Liu J, Yu M, Zhou C, et al. Renal clearable inorganic nanoparticles: a new frontier of bionanotechnology. Mater Today. 2013;16(12):477–486.
   Web of Science ®Google Scholar
• Kim J, Archer PA, Thomas SN. Innovations in lymph node targeting nanocarriers. Semin Immunol. 2021;56:101534.
   PubMed Web of Science ®Google Scholar
• Goldberg MS. Improving cancer immunotherapy through nanotechnology. Nat Rev Cancer. 2019;19(10):587–602.
   PubMed Web of Science ®Google Scholar
• Inoue H, Tani K. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Diff. 2014;21(1):39–49.
   PubMed Web of Science ®Google Scholar
• Verfaillie T, Garg AD, Agostinis P. Targeting ER stress induced apoptosis and inflammation in cancer. Cancer Lett. 2013;332(2):249–264.
   PubMed Web of Science ®Google Scholar
• Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3(5):380–387.
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860–875.
   PubMed Web of Science ®Google Scholar
• Inglut CT, Gaitan B, Najafali D, et al. Predictors and limitations of the penetration depth of photodynamic effects in the rodent brain. Photochem Photobiol. 2020;96(2):301–309.
   PubMedGoogle Scholar
• Larue L, Myrzakhmetov B, Ben-Mihoub A, et al. Fighting hypoxia to improve PDT. Pharmaceuticals. 2019;12(4):163.
   Google Scholar
• Schumacher Ton N, Schreiber Robert D. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69–74.
   PubMedGoogle Scholar
• Schumacher TN, Scheper W, Kvistborg P. Cancer Neoantigens. Annu Rev Immunol. 2018;37(1):173–200.
   PubMedGoogle Scholar
• Zhang Z, Lu M, Qin Y, et al. Neoantigen: a new breakthrough in tumor immunotherapy. Front Immunol. 2021;12:1297.
   Google Scholar
• Chu Y, Liu Q, Wei J, et al. Personalized cancer neoantigen vaccines come of age. Theranostics. 2018;8(15):4238–4246.
   PubMed Web of Science ®Google Scholar
• Xiao P, Wang J, Fang L, et al. Nanovaccine-mediated cell selective delivery of neoantigens potentiating adoptive dendritic cell transfer for personalized immunization. Adv Funct Mater. 2021;31(36):2104068.
   Google Scholar
• Wang Y, Zhao Q, Zhao B, et al. Remodeling tumor-associated neutrophils to enhance dendritic cell-based HCC neoantigen nano-vaccine efficiency. Adv Sci. 2022;n/a(n/a):2105631.
   Google Scholar
• Xu C, Nam J, Hong H, et al. Positron emission tomography-guided photodynamic therapy with biodegradable mesoporous silica nanoparticles for personalized cancer immunotherapy. ACS Nano. 2019;13(10):12148–12161.
   PubMed Web of Science ®Google Scholar
• Li Z, Barnes JC, Bosoy A, et al. Mesoporous silica nanoparticles in biomedical applications. Chem Soc Rev. 2012;41(7):2590–2605.
   PubMed Web of Science ®Google Scholar
• Wang Q, Ju X, Wang J, et al. Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies. Cancer Lett. 2018;438:17–23.
   PubMed Web of Science ®Google Scholar
• Pol J, Vacchelli E, Aranda F, et al. Trial Watch: immunogenic cell death inducers for anticancer chemotherapy. OncoImmunology. 2015;4(4):e1008866.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Humeau J, Buqué A, et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17(12):725–741.
   PubMed Web of Science ®Google Scholar
• Mautino MR, Jaipuri FA, Waldo J, et al. Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. Cancer Res. 2013;73(8_Supplement):491.
   Google Scholar
• Labadie BW, Bao R, Luke JJ. Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan–kynurenine–aryl hydrocarbon axis. Clin Cancer Res. 2019;25(5):1462–1471.
   PubMed Web of Science ®Google Scholar
• Zakharia Y, McWilliams RR, Rixe O, et al. Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma. J ImmunoTher Cancer. 2021;9(6):e002057.
   PubMedGoogle Scholar
• Zakharia Y, Rixe O, Ward JH, et al. Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma. J Clin Oncol. 2018;36(15_suppl):9512.
   Google Scholar
• Lu J, Liu X, Liao Y-P, et al. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nat Commun. 2017;8(1):1811.
   PubMed Web of Science ®Google Scholar
• Mei K-C, Liao Y-P, Jiang J, et al. Liposomal delivery of mitoxantrone and a cholesteryl indoximod prodrug provides effective chemo-immunotherapy in multiple solid tumors. ACS Nano. 2020;14(10):13343–13366.
   PubMed Web of Science ®Google Scholar
• Wan Z, Sun J, Xu J, et al. Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy. Acta Biomater. 2019;90:300–313.
   PubMed Web of Science ®Google Scholar
• Liu Y, Bhattarai P, Dai Z, et al. Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer. Chem Soc Rev. 2019;48(7):2053–2108.
   PubMed Web of Science ®Google Scholar
• Chen Q, Xu L, Liang C, et al. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nat Commun. 2016;7(1):13193.
   PubMed Web of Science ®Google Scholar
• Li S, Feng X, Wang J, et al. Polymer nanoparticles as adjuvants in cancer immunotherapy. Nano Res. 2018;11(11):5769–5786.
   Web of Science ®Google Scholar
• Seremet T, Brasseur F, Coulie PG. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy. Cancer J. 2011;17(5):325–330.
   PubMedGoogle Scholar
• Balakrishnan PB, Sweeney EE, Ramanujam AS, et al. Photothermal therapies to improve immune checkpoint blockade for cancer. Int J Hyperther. 2020;37(3):34–49.
   PubMed Web of Science ®Google Scholar
• Liu Y, Crawford BM, Vo-Dinh T. Gold nanoparticles-mediated photothermal therapy and immunotherapy. Immunotherapy. 2018;10(13):1175–1188.
   PubMed Web of Science ®Google Scholar
• Wang L, He Y, He T, et al. Lymph node-targeted immune-activation mediated by imiquimod-loaded mesoporous polydopamine based-nanocarriers. Biomaterials. 2020;255:120208.
   PubMed Web of Science ®Google Scholar
• Xu L, Zhang W, Park H-B, et al. Indocyanine green and poly I:C containing thermo-responsive liposomes used in immune-photothermal therapy prevent cancer growth and metastasis. J ImmunoTher Cancer. 2019;7(1):220.
   PubMed Web of Science ®Google Scholar
• Chen P-M, Pan W-Y, Wu C-Y, et al. Modulation of tumor microenvironment using a TLR-7/8 agonist-loaded nanoparticle system that exerts low-temperature hyperthermia and immunotherapy for in situ cancer vaccination. Biomaterials. 2020;230:119629.
   PubMed Web of Science ®Google Scholar
• Golden EB, Apetoh L. Radiotherapy and immunogenic cell death. Semin Radiat Oncol. 2015;25(1):11–17.
   PubMed Web of Science ®Google Scholar
• Vanmeerbeek I, Sprooten J, De Ruysscher D, et al. Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. OncoImmunology. 2020;9(1):1703449.
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168.
   PubMed Web of Science ®Google Scholar
• Deveuve Q, Lajoie L, Barrault B, et al. The proteolytic cleavage of therapeutic monoclonal antibody hinge region: more than a matter of subclass. Front Immunol. 2020;11:168.
   PubMedGoogle Scholar
• Kwon M, Jung H, Nam G-H, et al. The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy. J Control Release. 2021;331:321–334.
   PubMed Web of Science ®Google Scholar
• Pham LM, Poudel K, Ou W, et al. Combination chemotherapeutic and immune-therapeutic anticancer approach via anti-PD-L1 antibody conjugated albumin nanoparticles. Int J Pharm. 2021;605:120816.
   PubMedGoogle Scholar
• Liu Y, Chen X-G, Yang -P-P, et al. Tumor microenvironmental pH and enzyme dual responsive polymer-liposomes for synergistic treatment of cancer immuno-chemotherapy. Biomacromolecules. 2019;20(2):882–892.
   PubMed Web of Science ®Google Scholar
• Moon Y, Shim MK, Choi J, et al. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death. Theranostics. 2022;12(5):1999–2014.
   PubMed Web of Science ®Google Scholar
• Shim MK, Moon Y, Yang S, et al. Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy. Biomaterials. 2020;261:120347.
   PubMed Web of Science ®Google Scholar
• Um W, Park J, Ko H, et al. Visible light-induced apoptosis activatable nanoparticles of photosensitizer-DEVD-anticancer drug conjugate for targeted cancer therapy. Biomaterials. 2019;224:119494.
   PubMedGoogle Scholar
• Shim MK, Park J, Yoon HY, et al. Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy. J Control Release. 2019;294:376–389.
   PubMed Web of Science ®Google Scholar
• Cho IK, Shim MK, Um W, et al. Light-activated monomethyl auristatin E prodrug nanoparticles for combinational photo-chemotherapy of pancreatic cancer. Molecules. 2022;27(8):2529.
   PubMedGoogle Scholar
• Cho H, Shim MK, Yang S, et al. Cathepsin B-overexpressed tumor cell activatable albumin-binding doxorubicin prodrug for cancer-targeted therapy. Pharmaceutics. 2022;14(1):83.
   Google Scholar
• Kim J, Shim MK, Cho Y-J, et al. The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis. Biomaterials. 2021;279:121189.
   PubMed Web of Science ®Google Scholar
• Kim J, Shim MK, Yang S, et al. Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance. J Control Release. 2021;330:920–932.
   PubMed Web of Science ®Google Scholar